Lyra Therapeutics (LYRA) Return on Invested Capital (2023 - 2025)
Historic Return on Invested Capital for Lyra Therapeutics (LYRA) over the last 3 years, with Q3 2025 value amounting to 26.11%.
- Lyra Therapeutics' Return on Invested Capital rose 300400.0% to 26.11% in Q3 2025 from the same period last year, while for Sep 2025 it was 26.11%, marking a year-over-year increase of 300400.0%. This contributed to the annual value of 1.91% for FY2024, which is 11200.0% down from last year.
- According to the latest figures from Q3 2025, Lyra Therapeutics' Return on Invested Capital is 26.11%, which was up 300400.0% from 15.12% recorded in Q2 2025.
- In the past 5 years, Lyra Therapeutics' Return on Invested Capital ranged from a high of 26.11% in Q3 2025 and a low of 15.12% during Q2 2025
- Its 3-year average for Return on Invested Capital is 1.64%, with a median of 2.94% in 2024.
- Data for Lyra Therapeutics' Return on Invested Capital shows a peak YoY increase of 300400bps (in 2025) and a maximum YoY decrease of -131700bps (in 2025) over the last 5 years.
- Lyra Therapeutics' Return on Invested Capital (Quarter) stood at 0.77% in 2023, then tumbled by -673bps to 5.98% in 2024, then skyrocketed by 536bps to 26.11% in 2025.
- Its last three reported values are 26.11% in Q3 2025, 15.12% for Q2 2025, and 10.56% during Q1 2025.